Search research articles
Contact Us
Filters
Showing results (41-50 of 58) with videos related to
Page
of 6
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)
|
October 31, 2013
Safety, tolerability, and immunogenicity of repeated doses of dermavir, a candidate therapeutic HIV vaccine, in HIV-infected patients receiving combination antiretroviral therapy: results of the ACTG 5176 trial
Benigno Rodriguez, David M Asmuth, Roy M Matining, et al.
Antiviral Research
|
October 23, 2004
A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis
Michael J Borucki, John Spritzler, David M Asmuth, et al.
The Journal of Infectious Diseases
|
October 3, 2017
Tissue Pharmacologic and Virologic Determinants of Duodenal and Rectal Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution in HIV-Infected Patients Initiating Antiretroviral Therapy
David M Asmuth, Corbin G Thompson, Tae-Wook Chun, et al.
Plos One
|
January 30, 2020
HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens
Gregory D Huhn, Moti Ramgopal, Mamta K Jain, et al.
The Journal of Infectious Diseases
|
November 26, 2009
Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens
David M Asmuth, Elizabeth L Brown, Mark J DiNubile, et al.
The Lancet. HIV
|
July 1, 2021
Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial
Onyema Ogbuagu, Peter J Ruane, Daniel Podzamczer, et al.
The Journal of Infectious Diseases
|
April 28, 2010
Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial
David M Asmuth, Robert L Murphy, Susan L Rosenkranz, et al.
Plos Pathogens
|
May 4, 2017
Correction: Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial
Sergio Serrano-Villar, Talia Sainz, Zhong-Min Ma, et al.
Blood
|
April 22, 2009
IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection
Irini Sereti, Richard M Dunham, John Spritzler, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
March 26, 2011
Molecular characterization of stool microbiota in HIV-infected subjects by panbacterial and order-level 16S ribosomal DNA (rDNA) quantification and correlations with immune activation
Collin L Ellis, Zhong-Min Ma, Surinder K Mann, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 58) with videos related to
Sort By:
Page
of 6
Journal of Acquired Immune Deficiency Syndromes (1999)
|
October 31, 2013
Safety, tolerability, and immunogenicity of repeated doses of dermavir, a candidate therapeutic HIV vaccine, in HIV-infected patients receiving combination antiretroviral therapy: results of the ACTG 5176 trial
Benigno Rodriguez, David M Asmuth, Roy M Matining, et al.
Antiviral Research
|
October 23, 2004
A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis
Michael J Borucki, John Spritzler, David M Asmuth, et al.
The Journal of Infectious Diseases
|
October 3, 2017
Tissue Pharmacologic and Virologic Determinants of Duodenal and Rectal Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution in HIV-Infected Patients Initiating Antiretroviral Therapy
David M Asmuth, Corbin G Thompson, Tae-Wook Chun, et al.
Plos One
|
January 30, 2020
HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens
Gregory D Huhn, Moti Ramgopal, Mamta K Jain, et al.
The Journal of Infectious Diseases
|
November 26, 2009
Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens
David M Asmuth, Elizabeth L Brown, Mark J DiNubile, et al.
The Lancet. HIV
|
July 1, 2021
Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial
Onyema Ogbuagu, Peter J Ruane, Daniel Podzamczer, et al.
The Journal of Infectious Diseases
|
April 28, 2010
Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial
David M Asmuth, Robert L Murphy, Susan L Rosenkranz, et al.
Plos Pathogens
|
May 4, 2017
Correction: Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial
Sergio Serrano-Villar, Talia Sainz, Zhong-Min Ma, et al.
Blood
|
April 22, 2009
IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection
Irini Sereti, Richard M Dunham, John Spritzler, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
March 26, 2011
Molecular characterization of stool microbiota in HIV-infected subjects by panbacterial and order-level 16S ribosomal DNA (rDNA) quantification and correlations with immune activation
Collin L Ellis, Zhong-Min Ma, Surinder K Mann, et al.
Page
of 6